DiaMedica Therapeutics Inc. Profile Avatar - Palmy Investing

DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX tria…

Biotechnology
US, Minneapolis [HQ]
Growth Rates · Payout · Yield

Dividends Over Time

  • Records
  • Forecasts [Soon]
Growth Rates
0.00% YoY
0.00% 3Yr
0.00% 5Yr
0.00% 10Yr
Key Metrics
- -% TTM Yield
- - Average Days Gap
Series
% - - Yield
0.00% Payout Ratio
Cash Amount Pay Date
Cash Amount Pay Date
End of DMAC's Analysis
CIK: 1401040 CUSIP: 25253X207 ISIN: CA25253X2077 LEI: - UEI: -
Secondary Listings
DMAC has no secondary listings inside our databases.